Hong Kong Industrials Stock News

As global markets face challenges such as AI valuation concerns and economic uncertainties, Asian stocks have shown resilience with some indices reaching new highs. In this environment, identifying undervalued stocks becomes crucial, as they may offer potential opportunities for investors seeking to capitalize on discrepancies between market price and intrinsic value.

Sam Woo Construction Group Limited ( HKG:3822 ) shares have continued their recent momentum with a 34% gain in the last...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

With a price-to-earnings (or "P/E") ratio of 4.7x Vodatel Networks Holdings Limited ( HKG:8033 ) may be sending very...

Trio Industrial Electronics Group Limited ( HKG:1710 ) shares have continued their recent momentum with a 33% gain in...

To the annoyance of some shareholders, FDB Holdings Limited ( HKG:1826 ) shares are down a considerable 29% in the last...

It's nice to see the Shandong Hi-Speed New Energy Group Limited ( HKG:1250 ) share price up 14% in a week. But that...

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'd want to...

The SPT Energy Group Inc. ( HKG:1251 ) share price has fared very poorly over the last month, falling by a substantial...

Amid the evolving global economic landscape, Asian markets have shown resilience, with Chinese indices experiencing gains due to easing trade tensions. In this context, penny stocks—often smaller or newer companies—remain a noteworthy investment area despite their historical connotations. These stocks can offer a unique blend of affordability and growth potential when backed by strong financials, making them intriguing options for investors seeking opportunities beyond mainstream equities.

SANVO Fine Chemicals Group Limited ( HKG:301 ) shares have had a really impressive month, gaining 32% after a shaky...

In recent days, Hong Kong’s economy has shown resilience with 3.8% GDP growth and rising retail sales, providing support to key developers like China Resources Land. A recent U.S.-China trade truce and tariff reductions offer further relief to companies involved in cross-border property markets, even as China faces manufacturing headwinds. To assess what this means for China Resources Land, we’ll explore how Hong Kong’s strong economic performance influences the company’s investment...

Hong Kong Exchanges and Clearing (SEHK:388) just released its latest earnings, showing a clear jump in both revenue and net income for the third quarter and the year to date, compared to last year. See our latest analysis for Hong Kong Exchanges and Clearing. Strong results have helped drive Hong Kong Exchanges and Clearing’s share price up by more than 50% year-to-date. Its total shareholder return over the past year reached an impressive 37%. That momentum reflects renewed optimism...

COSCO SHIPPING Ports (SEHK:1199) released its third quarter and nine-month earnings, drawing attention for showing higher sales and net income compared to last year. Investors are likely watching to see how these stronger results play out. See our latest analysis for COSCO SHIPPING Ports. The recent bump in nine-month earnings has come as COSCO SHIPPING Ports' share price has gained steady ground, up 29.3% year-to-date and closing at $5.91. With a 43.6% total return for the year, the stock's...

RemeGen (SEHK:9995) just posted stronger sales numbers and trimmed its net loss for the first nine months of 2025. At the same time, new study results for its telitacicept drug are bolstering investor confidence. See our latest analysis for RemeGen. RemeGen’s stock has been volatile but delivered impressive gains for investors this year, with the share price up 524% year-to-date and a one-year total shareholder return of nearly 340%. After spiking sharply on optimism about its clinical...

Alphamab Oncology recently announced that its drug candidate JSKN003 has received Fast Track Designation from the U.S. FDA for the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer, without restriction by HER2 expression. This regulatory milestone builds on promising international clinical trial data and highlights momentum in Alphamab's pipeline of antibody-based oncology therapies. We'll explore how the U.S. FDA's Fast...

China Overseas Property Holdings Limited announced that, following a board meeting on October 28, 2025, Mr. Pang Jinying resigned from his roles as Executive Director, Vice President, and alternate to the authorised representative due to a realignment of work duties. This departure marks a significant leadership transition and raises important considerations about continuity in management and overall corporate governance. We will assess how this key executive change could influence investor...

InnoCare Pharma recently announced two important milestones: the first patient was dosed in a Chinese clinical trial for its novel B7-H3 targeted ADC (ICP-B794), and encouraging new phase I/II clinical data on zurletrectinib for pediatric and adolescent solid tumors was shared at an international oncology congress. Of particular note, ICP-B794 addresses a significant unmet need as there are currently no B7-H3 targeted therapies approved for marketing globally, highlighting InnoCare’s focus...

Earlier this month, Dongfang Electric Corporation Limited released earnings results for the nine months ended September 30, 2025, reporting sales of CNY 54.74 billion and net income of CNY 2.97 billion, both higher than the same period last year. The company also announced plans to amend its Articles of Association, with changes pending shareholder approval at an upcoming extraordinary general meeting. We'll explore how Dongfang Electric's strong earnings growth reinforces its investment...

Geely Automobile Holdings reported unaudited group vehicle sales for October 2025, delivering 307,133 units for the month and 2.48 million units year-to-date, both substantially higher than the corresponding periods last year. This sharp rise in sales volume highlights strong demand and could be seen as a reflection of Geely's expansion efforts and product appeal in an increasingly competitive market. We'll examine how Geely's record monthly and year-to-date sales performance informs its...

Ascletis Pharma announced positive Phase Ib results for its ASC30 oral and subcutaneous formulations, showing notable placebo-adjusted mean body weight reduction, a favorable safety profile, and ultra-long half-lives supporting both monthly and quarterly dosing, with these updates presented recently at ObesityWeek 2025. The company also unveiled new preclinical results where a combination of ASC47 and ASC31 outperformed monotherapies in promoting both weight and fat loss, and advanced its...

China Life Insurance reported earnings for the nine months ended September 30, 2025, with net income reaching CNY167.80 billion, up from CNY104.52 billion a year earlier, and basic earnings per share from continuing operations rising to CNY5.94. New agreements on insurance fund investment management and the renewal of key connected transactions reflect ongoing efforts to strengthen investment oversight and enhance compliance, potentially influencing operational efficiency. We'll examine how...

China XLX Fertiliser (SEHK:1866) has started a share buyback program after approval at its recent Annual General Meeting. The company now has permission to repurchase up to 10% of its outstanding shares. This move can boost earnings per share and reflects faith in the company's outlook. See our latest analysis for China XLX Fertiliser. After a sharp rally this year, China XLX Fertiliser’s share price has climbed 94.5% year-to-date. This reflects stronger sentiment and optimism following the...

China Resources Mixc Lifestyle Services (SEHK:1209) recently renewed several framework agreements with affiliated entities, covering procurement, value-added services, property management, and membership operations. These moves highlight the company's ongoing efforts to secure stable and recurring revenue streams while fostering reliable business relationships. See our latest analysis for China Resources Mixc Lifestyle Services. Momentum is clearly building for China Resources Mixc Lifestyle...